A very small segment of the Medicaid-only population-those who are not also eligible for Medicare-accounted for almost half of expenditures for all Medicaid-only enrollees from 2009 to 2011, according to a new report from the Government Accountability Office.
A very small segment of the Medicaid-only population—those who are not also eligible for Medicare—accounted for almost half of expenditures for all Medicaid-only enrollees from 2009 to 2011, according to a new report from the Government Accountability Office (GAO).
While the most expensive 5% accounted for nearly half of expenditures, the least expensive 50% of Medicaid-only enrollees accounted for less than 8% of expenditures for this population. In addition, about 12% of enrollees had no expenditures.
GAO found that the distribution of high-expenditure enrollees' spending among categories of service varied widely across states. In Tennessee the most expensive 5% accounted for 28.8% of spending, while in California they represented 63.2%. Expenditures for managed care and premium assistance varied the most widely from 0% to 75%.
The report examined the percentages of enrollees with any of 5 chronic conditions: asthma, diabetes, HIV/AIDS, mental health conditions, and substance abuse. In addition, they examined expenditures in 8 categories of services: hospital, long-term, psychiatric facility, acute care, long-term support, other support services (such as targeted case management or rehabilitative services), prescription drugs, and managed care and premium assistance.
“Differences between the high-expenditure Medicaid-only enrollees and the larger group of all Medicaid-enrollees were also consistent across years: In each year, the percentage of high-expenditure Medicaid-only enrollees who had any one of these conditions or services was greater than the percentage of all Medicaid-only enrollees who had that same condition or service,” according to the report.
Less than 15% of all Medicaid-only enrollees had mental health conditions, but those with mental health conditions accounted for approximately half of the high-expenditure group each year. Only 3% of all Medicaid-only enrollees had diabetes, but they constituted nearly 20% of the high-expenditure group.
The researchers also highlighted varying percentages of high-expenditure Medicaid-only enrollees’ spending in select categories. While psychiatric facility care only accounted for about 2% of nationwide expenditures for high-expenditure Medicaid-only enrollees, it varied from 0% to 11% across states. Other categories had even larger variations: 0% to 33% for acute care service;, 0% to 25% for prescription drugs; 0% to 23% for long-term non-institutional support services; and 0% to 22% for long-term institutional care.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More